EML4/ALK fusion

Pfizer completed submission of its NDA for the ALK-inhibiting non-small cell lung cancer drug crizotinib, and was granted a priority review from the FDA. Meantime, Abbott Molecular plans to submit "shortly" a premarket approval application for a commercial companion diagnostic that will pick out best responders to crizotinib.

The drug/diagnostic codevelopment partners are each planning to complete regulatory submissions with the FDA in the first half of this year for a pharmacogenomic NSCLC treatment targeting patients with the EML4-ALK-fusion oncogene.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.